Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?
1 July 2021
The Value in Health May issue includes the paper “How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?”. Finalised in December 2020, it includes:…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
As the world is figuring out how to deal with COVID-19, it is worth taking stock of the broader value that existing vaccines bring to societies…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
Berdud, Drummond and Towse (2020) propose a method for establishing a reasonable price for an orphan drug. Assuming prices for drugs are set according to incremental…